Recent news highlights include positive data from the extension phase of the Phase 2a CBeyond trial in obesity, ongoing clinical development efforts, and strategic collaborations. The Phase 2a monotherapy study did not meet its primary endpoint, impacting clinical progress. Analyst coverage and R&D investment have increased, reflecting active development.

• Skye reported positive data from the extension phase of the Phase 2a CBeyond trial in obesity, indicating ongoing clinical evaluation of nimacimab [N2].
• The Phase 2a CBeyond study of nimacimab monotherapy did not meet its primary endpoint, representing a setback in clinical development [N5].
• HC Wainwright & Co. initiated coverage of Skye Bioscience with a buy recommendation, reflecting analyst interest [N6].
• The company reported a 249% increase in R&D expenses in Q2 2025 with no revenue, consistent with its clinical-stage status [N8].
• Skye entered into a collaboration with Halozyme for ENHANZE drug delivery technology to develop a subcutaneous formulation of nimacimab, including milestone and royalty payments [S1,N2].
• Recent news also includes broader biotech sector momentum and data anticipation impacting stock activity [N3].

Nimacimab's novel mechanism as a peripherally restricted CB1 negative allosteric modulator and inverse agonist could provide a safer and more effective treatment for obesity and metabolic disorders compared to existing therapies. Positive preclinical data demonstrating weight loss with lean mass preservation and glycemic improvements, along with potential combination benefits with incretin therapies, support its therapeutic promise. The company's collaboration with Halozyme for advanced drug delivery and ongoing clinical development efforts may enhance patient compliance and commercial viability. If nimacimab advances successfully through clinical trials, it could address significant unmet medical needs in a large and growing obesity market.

Skye Bioscience faces significant risks including the failure of nimacimab to demonstrate clinical efficacy, as evidenced by the Phase 2a CBeyond study not meeting its primary endpoint. The company has no approved products and depends entirely on the success of nimacimab. Financially, it has incurred substantial losses with limited cash reserves and substantial doubt about its ability to continue as a going concern beyond late 2026 without additional financing. Manufacturing reliance on third parties and the need for further capital raise add operational risks. Competition from established and emerging obesity therapies, regulatory challenges, and potential safety issues remain key concerns.

Skye Bioscience's moat is based on its proprietary large-molecule antibody nimacimab that targets the CB1 receptor with a unique negative allosteric modulation and inverse agonism mechanism. This approach aims to overcome safety limitations of prior small molecule CB1 inhibitors by avoiding blood-brain barrier penetration, potentially offering a differentiated safety and tolerability profile. The company's intellectual property, clinical data, and strategic partnerships, including the Halozyme collaboration for drug delivery, contribute to its competitive positioning. However, as a clinical-stage company with no approved products, the moat is contingent on successful clinical development and regulatory approval.

• Clinical Development Risk: Nimacimab has not yet demonstrated definitive clinical efficacy; failure in clinical trials could delay or prevent regulatory approval.
• Financial Risk: The company has incurred significant losses and has limited cash resources, with substantial doubt about its ability to continue as a going concern beyond late 2026 without additional financing.
• Manufacturing and Supply Risk: Skye relies on third-party contract manufacturing organizations for production of nimacimab, which may pose risks related to supply chain, quality, and scalability.
• Regulatory Risk: Approval of nimacimab depends on meeting regulatory requirements, which may be challenging given the novel mechanism and prior safety concerns with CB1 inhibitors.
• Competitive Risk: The obesity treatment market is competitive with established incretin therapies and emerging modalities; nimacimab must demonstrate clear differentiation to gain market acceptance.

• Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing next-generation molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic disorders [S1].
• The company's lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting the cannabinoid receptor 1 (CB1), a key GPCR involved in metabolic regulation [S1].
• Nimacimab is a humanized IgG4 antibody that binds specifically to CB1 with no cross-reactivity to CB2 and functions as a negative allosteric modulator and inverse agonist, inhibiting CB1 activity through a noncompetitive mechanism [S1].
• Nimacimab is designed to avoid penetration of the blood-brain barrier, potentially mitigating neuropsychiatric side effects seen with prior small molecule CB1 inhibitors [S1].
• The company completed acquisition of Bird Rock Bio, Inc. in August 2023, acquiring nimacimab [S1].
• Skye's strategy includes advancing nimacimab through clinical development for obesity and overweight as monotherapy and in combination with incretin-based therapies, exploring additional metabolic indications, pursuing strategic partnerships, and expanding its pipeline through in-licensing or acquisitions [S1].
• Nimacimab has demonstrated in preclinical diet-induced obesity mouse models significant dose-dependent weight loss, fat mass loss with lean mass preservation, and glycemic improvements; combination with tirzepatide showed additive weight loss effects [S1].
• Nonclinical studies in non-human primates showed a strong safety profile for nimacimab with no significant adverse effects and minimal brain exposure (~0.02%) [S1].
• Nimacimab supports once-monthly subcutaneous dosing due to its 18-22 day half-life, which may enhance patient compliance compared to daily oral dosing of small molecule CB1 inhibitors [S1].
• The company relies on third-party contract manufacturing organizations (CMOs) for production of nimacimab and is investing in manufacturing process and formulation optimization to support clinical and commercial needs [S1].
• In December 2025, Skye entered into a non-exclusive global collaboration and license agreement with Halozyme for ENHANZE drug delivery technology to develop a subcutaneous co-formulation with nimacimab, including milestone and royalty payments [S1,S22].
• As of December 31, 2025, Skye had cash and equivalents of approximately $5.9 million, short-term investments of about $19.9 million, current assets of $27.1 million, and current liabilities of $8.2 million, resulting in a current ratio of 3.3 and cash ratio of 3.14, indicating liquidity coverage for near-term obligations [S1].
• The company reported a net loss of $55.9 million and negative earnings per share of $1.41 for the fiscal year ended December 31, 2025, reflecting ongoing development expenses and no product revenue [S1].
• Management estimates sufficient capital to continue operations through Q4 2026 excluding costs for a proposed Phase 2b study and related manufacturing [S1].
• Skye has a limited operating history, no approved products, and depends heavily on successful development and commercialization of nimacimab [S1].
• The company has 12 full-time employees as of March 9, 2026, including four with Ph.D. or MD degrees, and relies on consultants and CROs for development activities [S1].
• Recent news highlights include positive data from the extension phase of the Phase 2a CBeyond trial in obesity, ongoing clinical development, and a collaboration with Halozyme for drug delivery technology [N2,N1].
• The Phase 2a CBeyond study of nimacimab monotherapy did not meet its primary endpoint, impacting clinical development progress [N5].
• HC Wainwright & Co. initiated coverage of Skye Bioscience with a buy recommendation in September 2025 [N6].
• The company reported a 249% increase in R&D expenses in Q2 2025 with no revenue, consistent with clinical-stage status [N8].